Physician profile
Sofia Carretero
NPI 1457956153
$2,092.96
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $817 · 2023: $346 · 2024: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.37 | 2021-2024 | Andexxa |
| Gilead Sciences, INC. | $202.14 | 2022-2024 | Veklury |
| Genzyme Corporation | $191.99 | 2022 | |
| Abbott Laboratories | $166.89 | 2024 | Proclaim |
| Glaxosmithkline, LLC. | $120.86 | 2024 | Nucala |
| Jazz Pharmaceuticals INC. | $119.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $118.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $115.61 | 2022 | |
| Stemline Therapeutics INC. | $115.61 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.97 | 2023 | |
| Medical Device Business Services, INC. | $99.74 | 2023 | Linx Reflux Management System |
| Eisai INC. | $89.67 | 2021 | |
| Novo Nordisk INC | $80.23 | 2021-2022 | |
| Coloplast Corp | $45.66 | 2023 | Titan, Altis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Carretero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.